27th Mar, 2017
Language Selection
Email
Zoosnet
Who we are
Why choose Fuda
Treatment guide
For your health
Fuda news
:
Cancer is a systemic disease with tumors as a local manifestation of the disease. Once cancer occurs in a person, cancerous cells will be found in the body. Surgical removal of tumors in no way implies that one is cured of cancer. For example, breast cancer can relapse even if the original tumors were removed.Like hypertension and diabetes, cancer is a chronic disease. The disease may take a few years to manifest itself - from its occurrence until the emergence of tumors. In some cases, cancer cells may exist in a stage of ....
:
:
:
:
Asia’s First Paper on NanoKnife Ablation for Liver Cancer Published in American Medical Journal_events_fuda news_Fuda Cancer Hospital Guangzhou_Cancer Treatment China_Tumor Technology_广州复大肿瘤医院_癌症治疗_微创治疗_癌症疗法
Asia’s First Paper on NanoKnife Ablation for Liver Cancer Published in American Medical Journal
Size: S / L
Previous
2016/12/1

 

Recently, the Nanoknife clinical research group of Guangzhou Fuda Cancer Hospital published one paper titled The Safety and Efficacy of Irreversible Electroporation for Large Hepatocellular Carcinoma [“不可逆电穿孔消融 (also called“纳米刀消融”) 治疗大肝癌的安全及疗效”] in American Academic Journal Technology in Cancer Research &Treatment, reporting their research achievements in Nanoknife ablation for large hepatocellular carcinoma.
 

It is found in Pubmed that it was the first clinical academic paper on Nanoknife Ablation for large hepatocellular carcinoma published worldwide, marking that China was leading the world in the clinical application of Nanoknife therapy.



 

Fuda’s first academic paper on Nanoknife Ablation for large hepatocellular carcinoma published in an authoritative American journal.
 



Pubmed website


 

The paper was coauthored by minimally invasive interventional surgery group and central laboratory research group of Guangzhou Fuda Cancer Hospital. During the clinical research, minimally invasive interventional surgery group divided 14 liver cancer patients into two groups. The first group was composed of eight patients with large hepatocellular carcinoma, whose cancer were between 5.1cm and 11.5cm in diameter. The second group had 6 patients with medium hepatocellular carcinoma, whose cancer were between 3.0cm to 4.1cm in diameter. All patients from these two groups were treated by Nanoknife ablation.

 

The results showed that in the first group patients (with large hepatocellular carcinoma) had no major complications, and some had minor complications and their conditions were improved after symptomatic treatments. In the second group, the rate of patients having mild complications had no distinct difference with that of the first group, and the tumor ablation rate in this group is 66.6%.



 

 

Fuda's first academic paper on Nanoknife Ablation for large hepatocellular carcinoma included in an authoritative American journal.

 

 

Dr. Niu Lizhi, chief expert of minimally invasive interventional surgery group and president of Guangzhou Fuda Cancer Hospital, said, “This is Asia’s first clinical paper on IRE (Irreversible Electroporation) that has SCI impact factor. The research shows that applying Nanoknife ablation to treat large hepatocellular carcinoma is safe and its short-term effect is very good, especially it a better option for those with unresectable hepatocellular carcinoma.”

 

The paper also pointed out the morbidity of primary liver cancer in China and Southeast Asia was 5~8 times higher than that of the US and Europe. Though the preferred choice for treating primary liver cancer was radical resection, it was only suitable for less than 20% of patients.

 

Radio frequency ablation, microwave ablation and cryoablation are increasingly applied to treat unresectable liver cancer, yet they all have their limitations. Compared to traditional ablation techniques, Nanoknife ablation has distinct advantages in treating liver tumors close to important organs like hilar, vessel, bile duct, gallbladder etc. Nanoknife Ablation can be used clinically for unresectable liver tumors. 



 

 

Fuda's first academic paper on Nanoknife Ablation for large hepatocellular carcinoma included in an authoritative American journal.
 

 

Fuda Cancer Hospital has brought in this advanced technique since China approved the clinical application of Nanoknife ablation in July, 2015. Fuda is the first hospital that started applying this technique in China, and also the one that has treated the most patients using Nanoknife ablation. The technique has very good effect especially in dealing with liver cancer and pancreatic cancer.

 

 

 

Who we are
Why choose Fuda
Treatment guide
For your health
版权所有 Copyright (c) 2013 by fudahospital.com. All Rights Reserved.
· 粤ICP备13048536号 · 工信部网址 · 安全检测 ·